Tourmaline Bio Stock (NASDAQ:TRML)

Forecast Revenue Ownership Financials Chart

Previous Close

$24.52

52W Range

$12.12 - $48.31

50D Avg

$25.40

200D Avg

$22.17

Market Cap

$602.60M

Avg Vol (3M)

$220.29K

Beta

-

Div Yield

-

TRML Company Profile

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

74

IPO Date

May 07, 2021

Website

TRML Performance

TRML Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-45.41M	$-19.70M	$-904.00
Net Income	$-42.12M	$-19.70M	$-904.00
EBITDA	$-45.38M	$-19.70M	-
Basic EPS	$-2.07	$-0.97	-
Diluted EPS	$-2.07	$-0.97	-

Fiscal year ends in Dec 23 | Currency in USD